目的：根除性攝護腺切除和放射線治療是目前針對攝護腺癌的主要治療方式。本篇研究的目的是針對接受單獨放射線治療或放射線和荷爾蒙合併治療的攝護腺癌病人評估他們的治療效果和預後因子。
材料與方法：從2000年1月至2004年7月，總共有67個被診斷攝護癌的病人轉介到本院放射腫瘤科安排放射線治療。他們診斷年齡的中位數是75歲。在病理分類上全部屬於腺上皮癌。格里森分數（Gleason score）的中位數是6分。根據 1997年AJCC公布的分期系統，40個 （59.7%）病人屬於第二期，18個（26.9%）病人屬於第三期，9個（13.4%）病人屬於第四期。其中有4個病人沒有完成放射線治療而且沒有繼續在門診追蹤。在63個完成治療的病人之中，37個（58.7%）病人單獨接受放射線治療，26個（41.3%）病人接受放射線和荷爾蒙合併治療。放射線治療的方式是採用三度空間順形治療，劑量的中位數是72 Gy。本研究分析的變因包括：年齡、治療前的攝護腺特異抗原（PSA）、格里森分數、治療方式等，而且採用單一變項分析和多變項分析。單一變項分析是採用log rank test，而多變項分析是採用Cox proportional hazards model，存活率是以Kaplan-Meier計算。
結果：有2個病人在完成放射線治療後沒繼續在門診繼續追蹤。因此，最後只有61個病人進入分析。在存活率方面，5年整體存活率（overall survival）為 91.11%。5年的無臨床失敗存活率為70.15%。5年的無生化失敗存活率為56.50%。5年的疾病相關存活率（disease-specific survival）為93.57%。在單一變數分析中，治療前的攝護腺特異抗原（p = 0.0046）、格里森分化程度的最大值（p = 0.0481）對無生化失敗存活率是重要的預後因子。
結論：在此研究中，治療前攝護腺特異抗原較高、格里森分化程度最大值較高的病人其預後較差。對於這些病人可以考慮給予更積極的治療。

Purpose : Radical prostatectomy and radiation therapy are the main methods of treatment for prostate cancer. The goal of this study is to evaluate the outcomes and prognostic factors for patients with prostate cancer treated with radiation therapy alone or combined radiation and hormonal therapy.
Materials and Methods : From January 2000 through July 2004, there were 67 men diagnosed with prostate cancer and referred to radiation oncology for radiotherapy in our hospital. The median age of patients at the time of diagnosis was 75 years. The pathologic types were all adenocarcinoma. The median of Gleason score was 6. According to staging system of AJCC 1997, forty patients (59.7%) were stage II (T1N0M0 AnyG, T2N0M0 AnyG), eighteen patients (26.9%) were stage III (T3N0M0 AnyG), and 9 patients (13.4%) were stage IV (T4N0M0 AnyG, AnyTN1M0 AnyG). Four patients (6.0%) did not finish the radiation therapy course and were lost to follow up. Among the 63
patients who finished the therapy course, thirty-seven patients (58.7%) received radiotherapy alone, and 26 patients (41.3%) received combinations of radiation and hormonal therapy. The method of radiotherapy was 3-D conformal radiation therapy (3DCRT), and the median dose of radiation therapy was 7200 cGy. The variables, such as age, PSA level before treatment, Gleason score, maximum of Gleason grade, stage, methods of
treatment and dose of radiotherapy were analyzed with respect to their influence upon prognosis. Univariate and multivariate analyses were used. Univariate analysis using the log rank test and multivariate analysis using the Cox proportional hazards model were performed. Overall survival rate, disease-specific survival rate, survival rate without clinical
failure and survival rate without biochemical failure were calculated with the method of Kaplan and Meier.
Results : Two patients were lost to follow up after completion of radiotherapy. The median of follow-up duration was 27.8 months (range from 4.3 to 65.0 months). Therefore, sixty-one patients entered the analysis of results. Five-year overall survival rate was 91.11%. Five-year survival rate without clinical failure was 70.15%. Five-year survival rate without biochemical failure was 56.50%. Five-year disease-specific survival rate was93.57%. In univariate analysis of 3-year survival , PSA level before treatment and maximum of Gleason grade were significant predictors for survival rate without biochemical failure (p= 0.0046, 0.0481, respectively). Hormonal therapy was not a significant predictor for survival.
Conclusion : In this study, patients who had higher initial PSA level or maximum of Gleason grade had worse outcome. More aggressive treatment may be considered for these patients.